Evidence map›Paper›PMID 38658981›Full record

ArticleBiology direct2024

OTUD5 promotes the growth of hepatocellular carcinoma by deubiquitinating and stabilizing SLC38A1.

Yingnan Yang, Siying Jia, Ning Zhu, Xuelian Xiao, Ying Ma, Kangsheng Tu, Yong Guo, Qiuran Xu

Open access · goldAbstract read
In one paragraph

Article in Biology direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. OTU deubiquitinases in disease: roles and targeting.Trends in molecular medicine · 2026
    Review
  8. Review
  9. AKT and DUBs: a bidirectional relationship.Cellular & molecular biology letters · 2025
    Review
  10. Article
  11. Article
  12. Deubiquitylating Enzymes in Hepatocellular Carcinoma.International journal of biological sciences · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yingnan Yang *The Second Clinical Medical College of Zhejiang Chinese Medical University, 310053, Hangzhou, China.
Siying Jia *Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Ning Zhu *Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 310014, Hangzhou, China.
Xuelian XiaoDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Ying MaDepartment of Cardiovascular Medicine, The Affiliated Hospital of Northwest University, Xi'an No.3 Hospital, 710018, Xi'an, China.
Kangsheng TuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Yong GuoDepartment of Gastrointestinal Surgery, Shangluo Central Hospital, 726000, Shangluo, China. 353645263@qq.com.
Qiuran XuZhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 310014, Hangzhou, China. xuqiuran@hmc.edu.cn.ORCID 0000-0003-2171-9279
First Affiliated Hospital of Xi'an Jiaotong University · CNNorthwest University · CNShangluo Central Hospital · CNZhejiang Chinese Medical University · CNZhejiang Provincial People's Hospital · CN

Funding

Key Research and Development Projects of Shaanxi Province 2022SF- 586Key Research and Development Projects of Shaanxi Province 2023-YBSF-149
6 · The paper itself

Abstract

backgroundDeubiquitinating enzymes (DUBs) cleave ubiquitin on substrate molecules to maintain protein stability. DUBs reportedly participate in the tumorigenesis and tumour progression of hepatocellular carcinoma (HCC). OTU deubiquitinase 5 (OTUD5), a DUB family member, has been recognized as a critical regulator in bladder cancer, breast cancer and HCC. However, the expression and biological function of OTUD5 in HCC are still controversial.

resultsWe determined that the expression of OTUD5 was significantly upregulated in HCC tissues. High levels of OTUD5 were also detected in most HCC cell lines. TCGA data analysis demonstrated that high OTUD5 expression indicated poorer overall survival in HCC patients. OTUD5 silencing prominently suppressed HCC cell proliferation, while its overexpression markedly enhanced the proliferation of HCC cells. Mass spectrometry analysis revealed solute carrier family 38 member 1 (SLC38A1) as a candidate downstream target protein of OTUD5. Coimmunoprecipitation analysis confirmed the interaction between OTUD5 and SLC38A1. OTUD5 knockdown reduced and OTUD5 overexpression increased SLC38A1 protein levels in HCC cells. However, OTUD5 alteration had no effect on SLC38A1 mRNA expression. OTUD5 maintained SLC38A1 stability by preventing its ubiquitin-mediated proteasomal degradation. SLC38A1 silencing prominently attenuated the OTUD5-induced increase in HCC cell proliferation. Finally, OTUD5 knockdown markedly suppressed the growth of HCC cells in vivo.

conclusionsOTUD5 is an oncogene in HCC. OTUD5 contributes to HCC cell proliferation by deubiquitinating and stabilizing SLC38A1. These results may provide a theoretical basis for the development of new anti-HCC drugs.

Indexed as

Carcinoma, HepatocellularCell ProliferationLiver NeoplasmsAmino Acid Transport System AAnimalsCell Line, TumorDeubiquitinating EnzymesEndopeptidasesGene Expression Regulation, NeoplasticHumansMiceUbiquitinationAmino Acid Transport System ADeubiquitinating EnzymesEndopeptidasesOTUD5 protein, humanSLC38A1 protein, humanDeubiquitinating enzymesHepatocellular carcinomaOTUD5, SLC38A1, Tumour growth

Identifiers

PMID38658981
PMCPMC11041014
OpenAlexW4395081256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.